Ligand Pharmaceuticals Incorporated
LGND
株式のランク
#3113
Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity,... Ligand Pharmaceuticals Incorporated operates as a biopharmaceutical entity, primarily engaged in sourcing and advancing technologies to empower pharmaceutical companies globally in their efforts to discover and develop novel therapeutic solutions. Its diverse portfolio of commercialized products addresses a wide range of medical conditions. For hematologic malignancies, these include Kyprolis and Evomela, both targeting multiple myeloma, as well as Rylaze, a treatment for acute lymphoblastic leukemia and lymphoblastic lymphoma in both adult and pediatric patients. In the realm of infectious diseases, Ligand offers Veklury for moderate to severe COVID-19, Vaxneuvance for preventing invasive Streptococcus pneumoniae disease, and Pneumosil, a pneumococcal conjugate vaccine designed to protect children from pneumonia. Bone health solutions comprise Teriparatide injection for osteoporosis and Duavee for postmenopausal osteoporosis. Other key offerings include Zulresso, a Captisol-enabled formulation of brexanolone for postpartum depression; Nexterone, a Captisol-enabled amiodarone; and Noxafil-IV, a Captisol-enabled posaconazole for intravenous administration. The company’s comprehensive product lineup further extends to the Aziyo portfolio, featuring pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune disorders; Vivitra for breast cancer; Bryxta and Zybev for a variety of indications; and Minnebro for managing hypertension. Beyond its own commercialized products, Ligand Pharmaceuticals collaborates with partners on numerous programs currently undergoing clinical development, targeting conditions such as cancer, seizure disorders, diabetes, cardiovascular ailments, muscle wasting, hepatic and renal diseases, and various other serious illnesses. The company also directly supplies Captisol materials, a proprietary technology frequently integrated into many of its drug formulations. Established in 1987, Ligand Pharmaceuticals is headquartered in Emeryville, California.
株価
$291.18
最終同期: 2026-07-31
時価総額
$5.84B
変化（1日）
-1.73%
変化（1年）
55.99%
国
US
取引 Ligand Pharmaceuticals Incorporated (LGND)
カテゴリー
Healthcare
Ligand Pharmaceuticals Incorporated（LGND）の利益
Jun 2026 時点の利益 TTM: $237.96M
Ligand Pharmaceuticals Incorporated の最新の財務報告によると、同社の現在の利益は $237.96M です。2023 年には $63.66M の利益を上げ、これは 2022 年の利益 $36.01M と 増加 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Ligand Pharmaceuticals Incorporated の利益の推移（2000 〜 2026）
各年末の利益
| 年 | 利益 | 変化 |
|---|---|---|
| 2026 (TTM) | $237.96M | 9,350.44% |
| 2024 | $2.52M | -96.04% |
| 2023 | $63.66M | 76.78% |
| 2022 | $36.01M | -50.13% |
| 2021 | $72.21M | 5,488.62% |
| 2020 | $1.29M | -99.84% |
| 2019 | $796.64M | 359.61% |
| 2018 | $173.33M | 202.86% |
| 2017 | $57.23M | 618.98% |
| 2016 | $7.96M | -77.47% |
| 2015 | $35.33M | 212.59% |
| 2014 | $11.30M | 22.75% |
| 2013 | $9.21M | -338.21% |
| 2012 | $-3.87M | 31.91% |
| 2011 | $-2.93M | -80.98% |
| 2010 | $-15.40M | 56.03% |
| 2009 | $-9.87M | -89.88% |
| 2008 | $-97.52M | 82.42% |
| 2007 | $-53.46M | -69.33% |
| 2006 | $-174.27M | -579.56% |
| 2005 | $36.34M | -180.92% |
| 2004 | $-44.91M | 19.88% |
| 2003 | $-37.46M | 14.93% |
| 2002 | $-32.60M | 3.48% |
| 2001 | $-31.50M | -32.56% |
| 2000 | $-46.71M | 0.00% |
同業他社の利益
| 企業 | 利益 | 利益の差 | 国 |
|---|---|---|---|
| $5.27B | 2,116.70% |
US
|
|
| $-3.09B | -1,397.27% |
US
|
|
| $-4.02B | -1,787.75% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 719.73% |
NL
|
